Day: November 14, 2025

HOLMDEL, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced results for its third quarter (Q3’25) and nine months (9M’25) ended September 30, 2025. BIO-key is hosting an investor call today at 10:00am ET (details below). Recent HighlightsLaunched its next-generation EcoID III USB fingerprint scanner, delivering FBI FAP 20 certification, enhanced security, liveness detection and encrypted device-to-host communication. Partnered with IT2Trust, one of Scandinavia’s most established IT security and networking solutions providers to increase its access to key accounts across Denmark, Finland, Norway and Sweden. Showcased Solutions at Premier Tech and Cybersecurity Events in Europe, the Middle...

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Dotinurad, a next-generation URAT1 inhibitor, is advancing in two Phase 3 clinical trials with potential for best-in-class safety and efficacy following Crystalys Therapeutics’ $205 million Series A financing MIAMI, Nov. 14, 2025 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product...

Company Expects Continued, Sequential Topline Growth as well as Profitability in Q1 2026 NEWPORT BEACH, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today reported financial results for the third quarter ended September 30, 2025. Recent Operational HighlightsAcquired all of the assets of The Food Channel, a prominent digital platform dedicated to culinary content and inspiration, to strengthen Amaze’s culinary creator network. Unveiled Amaze Moments, an advanced AI engine designed to help creators and brands identify and act on spikes in traffic, fan engagement, and cultural relevance. Integrated with Dubit.io, one of the leading metaverse and gaming studios behind some of the world’s most engaging virtual experiences,...

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 – $6 million PIPE financing and a proposed Daewoong note exchange – are expected to strengthen AEON’s balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking an accelerated and...

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”, TSX: PVF.UN TSX: PVF.PR.U) announced today its financial results for the nine months ended September 30, 2025. All amounts are stated in U.S. dollars. The Partnership recorded net income of $27.1 million for the quarter ended September 30, 2025, compared to $14.6 million in the prior year quarter. The increase in income was primarily due to higher investment valuations gains, favorable foreign currency movements as a result of the depreciation of the Canadian dollar against the U.S. dollar and lower tax expense as compared to the prior year quarter. Income of $24.7 million was attributable to the Equity Limited Partners, and income of $2.4 million was attributable to Preferred Limited Partners. On August 8, 2025, the Partnership completed...

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Partners Value Investments Inc. (the “Company”, TSX: PVF.WT, PVF.PR.V, PVF.A) announced today its financial results for the nine months ended September 30, 2025. All amounts are stated in U.S. dollars. The Company recorded a net loss of $2.2 billion for the three months ended September 30, 2025, compared to a net loss of $1.2 billion in the prior year quarter. The increase in net loss was primarily due to current period remeasurement losses associated with the Company’s retractable common shares of $1.9 billion in the current quarter compared to remeasurement losses of $1.1 billion in the prior year quarter, remeasurement losses on warrants of $252 million in the current quarter compared to remeasurement losses of $114 million in the prior year quarter, and remeasurement losses on...

– Revenue of $6.4 million, 22% growth – Gross margin of 32% – Adjusted EBITDA margin of -3% due to a write-off – Successful entry into renewables – First Contracts in Brazil HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — KOIL Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its third quarter 2025 results. “We increased revenue by 22% this quarter; KOIL Energy is growing again,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “During the quarter KOIL Energy generated revenues of $6.4 million. These are clear indicators of strengthening demand both within services and products.” Third Quarter 2025 Results: For the three months ending September 30, 2025, Koil Energy generated revenues...

GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We continue to achieve meaningful milestones on our path toward U.S. Food and Drug Administration (FDA) approval and eventual commercialization of AD04, our lead investigational drug, a serotonin-3 receptor antagonist being developed for the treatment of Alcohol Use Disorder (AUD). A key highlight of our recent progress was the successful End of Phase 2 (EOP2) meeting with the FDA, where we received valuable guidance...